RLI Corp. (RLI) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +24.01%. A quarter ago, it was expected that this specialty insurance company would post earnings of $0.62 per share when it actually produced earnings of $0.83, delivering a surprise of +33.87%.Over the last four quarter ...

Core Insights - J.B. Hunt Transport Services (JBHT) reported mixed fourth-quarter 2025 earnings, with earnings per share surpassing estimates while revenues fell short [2][3]. Earnings Performance - JBHT's Q4 earnings were $1.90 per share, exceeding the Zacks Consensus Estimate of $1.81 and reflecting a 24.2% year-over-year improvement [4]. - Total operating revenues reached $3.09 billion, missing the Zacks Consensus Estimate of $3.12 billion and showing a 1.6% year-over-year decline [5]. Revenue Breakdown - Revenue per load excluding fuel surcharge revenue declined by 2% in Intermodal (JBI) and 4% in Truckload (JBT) [5]. - Average trucks in Dedicated Contract Services (DCS) decreased by 1%, while load volumes in Integrated Capacity Solutions (ICS) and JBI fell by 7% and 2%, respectively [5]. - A 15% increase in volume in JBT and a 1% increase in productivity in DCS partially offset the revenue decline [5]. Stock Performance - JBHT shares have outperformed the transportation-truck industry and the S&P 500 Index over the past six months [7]. - The stock's price performance is favorable compared to peers like Knight-Swift Transportation Holdings Inc. [7]. Valuation Metrics - JBHT's forward 12-month price-to-earnings ratio (P/E-F12M) is 28.15X, which is lower than the industry average of 30.18X, indicating an attractive valuation [11]. Financial Concerns - JBHT's cash and cash equivalents were $17.28 million at the end of Q4 2025, significantly lower than its short-term debt of $766.93 million, raising liquidity concerns [15]. - The current ratio was 0.83, indicating potential difficulties in meeting short-term obligations [15]. Investment Outlook - While JBHT's earnings performance is solid, potential investors are advised to exercise caution due to the company's financial challenges [16]. - Existing shareholders may consider maintaining their positions, as the long-term prospects remain positive, supported by a Zacks Rank 3 (Hold) [16].

Core Insights - Circle Internet Group, Inc. (CRCL) is positioned to continue its earnings-beat streak, having achieved an average surprise of 235.86% over the last two quarters [1][5] Earnings Performance - For the most recent quarter, Circle Internet Group reported earnings of $0.64 per share, exceeding the expected $0.20 per share, resulting in a surprise of 220.00% [2] - In the previous quarter, the company reported $1.02 per share against an expectation of $0.29 per share, leading to a surprise of 251.72% [2] Earnings Estimates and Predictions - Recent estimates for Circle Internet Group have been increasing, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong potential for another earnings beat [5][8] - The current Earnings ESP for the company is +0.51%, suggesting analysts are optimistic about its near-term earnings potential [8] Zacks Rank and Predictive Power - Circle Internet Group holds a Zacks Rank of 3 (Hold), which, when combined with a positive Earnings ESP, indicates a high likelihood of beating consensus estimates [6][8] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have historically produced positive surprises nearly 70% of the time [6]

Core Viewpoint - Houlihan Lokey (HLI) has a strong track record of exceeding earnings estimates and is well-positioned for future earnings growth, particularly with an average surprise of 17.75% over the past two quarters [1]. Earnings Performance - In the last reported quarter, Houlihan Lokey achieved earnings of $1.84 per share, surpassing the Zacks Consensus Estimate of $1.69 per share by 8.88% [2]. - In the previous quarter, the company reported earnings of $2.14 per share against an expected $1.69 per share, resulting in a surprise of 26.63% [2]. Earnings Estimates and Predictions - Estimates for Houlihan Lokey have been trending upward, influenced by its history of earnings surprises [4]. - The company currently has a positive Earnings ESP of +2.19%, indicating that analysts are optimistic about its earnings prospects [7]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat in the upcoming report [7]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [5]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [6].

Core Viewpoint - Raymond James Financial, Inc. (RJF) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for January 28, and better-than-expected results could lead to a stock price increase, while disappointing results may cause a decline [2]. - The consensus estimate for quarterly earnings is $2.83 per share, reflecting a year-over-year decrease of 3.4%, while revenues are projected to be $3.69 billion, up 4.2% from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 0.17% higher, indicating a collective reassessment by analysts [4]. - The Most Accurate Estimate for Raymond James Financial is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +0.67%, suggesting a bullish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, with a positive Earnings ESP indicating a higher likelihood of an earnings beat [8][9]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically produced positive surprises nearly 70% of the time [10]. Historical Performance - In the last reported quarter, Raymond James Financial exceeded the expected earnings of $2.7 per share, achieving actual earnings of $3.11, resulting in a surprise of +15.19% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Conclusion - Raymond James Financial is viewed as a strong candidate for an earnings beat, but investors should consider additional factors before making investment decisions [17].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for General Dynamics despite higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - General Dynamics is expected to report quarterly earnings of $4.10 per share, reflecting a year-over-year decrease of 1.2%, while revenues are projected to be $13.73 billion, an increase of 2.9% from the previous year [3]. - The consensus EPS estimate has been revised 0.05% higher in the last 30 days, indicating a slight positive adjustment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for General Dynamics is lower than the consensus estimate, resulting in an Earnings ESP of -1.04%, suggesting a bearish outlook [12]. - The stock holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, General Dynamics exceeded the expected earnings of $3.73 per share by delivering $3.88, resulting in a surprise of +4.02% [13]. - Over the past four quarters, the company has consistently beaten consensus EPS estimates [14]. Comparative Industry Analysis - Northrop Grumman, a competitor in the aerospace-defense industry, is expected to report earnings of $6.99 per share, a year-over-year increase of 9.4%, with revenues projected at $11.62 billion, up 8.7% [18][19]. - Northrop Grumman's consensus EPS estimate has been revised 0.1% higher, and it has an Earnings ESP of +0.54%, indicating a likelihood of beating the consensus estimate [19][20].

Core Viewpoint - Northern Trust Corporation (NTRS) is expected to report increased earnings and revenues for the fourth quarter and 2025, with results influenced by net interest income growth and asset management increases [1][8]. Financial Performance - In the last reported quarter, NTRS experienced an earnings surprise, benefiting from a rise in net interest income and increases in total assets under custody and management, although elevated expenses and reduced fee income were noted as concerns [2]. - The Zacks Consensus Estimate for NTRS' fourth-quarter earnings is $2.37 per share, reflecting a 4.9% increase year-over-year, while revenue estimates stand at $2.07 billion, indicating a 5.8% rise [3]. - The expected net interest income (NII) for the fourth quarter is $600.8 million, representing a 6.6% year-over-year increase, supported by stabilizing funding costs following recent Federal Reserve interest rate cuts [3][4]. Asset Management and Fees - The average earning assets are estimated at $142.5 billion, showing a significant 29% increase from the prior year [4]. - The Zacks Consensus Estimate for custody and fund administration fees is $488.7 million, indicating a 6.9% year-over-year rise, while investment management fees are expected to reach $167.4 million, up 6.7% from the previous year [6]. - Total wealth management fees are estimated at $580.7 million, reflecting a 6.2% increase year-over-year [6]. Operating Income and Expenses - Other operating income is projected at $59.2 million, which represents a 1.1% decline year-over-year [7]. - Total fee income is estimated at $1.47 billion, suggesting a 5% increase from the prior-year quarter [9]. - Elevated expenses are anticipated due to higher compensation costs and ongoing investments in technology infrastructure [9]. Asset Quality - Non-performing assets are expected to reach $82.9 million, indicating a significant 48% increase year-over-year, attributed to a slowdown in job growth potentially impacting consumer demand [10]. Earnings Prediction - The current Earnings ESP for NTRS is -0.38%, indicating that the model does not predict an earnings beat for this quarter [11]. The company holds a Zacks Rank of 3, suggesting a neutral outlook [12].

Group 1 - Moderna, Inc. is a leading biotechnology company known for its mRNA technology, particularly in COVID-19 vaccine development, competing with Pfizer and BioNTech [1] - Citigroup has updated its rating for Moderna to "Neutral," indicating that investors should hold onto the stock, which is currently trading at approximately $41.84 [1][5] - The stock has seen a 6.29% increase, with a daily trading range between $40.55 and $42.30, and a market capitalization of around $16.35 billion [4][5] Group 2 - Investors often focus on stocks that are expected to exceed quarterly earnings estimates, as these can significantly influence stock prices [2] - The Zacks Earnings ESP tool is utilized to identify potential earnings surprises by analyzing recent analyst revisions, which can help investors enhance their returns [3]

Core Viewpoint - Alcoa Corporation is set to report its fourth-quarter 2025 results on January 22, with earnings estimates showing an 18.8% increase over the past 60 days, but a projected decline of 8.7% year-over-year in earnings and a 7% decline in revenues [1][7]. Earnings Estimates - The Zacks Consensus Estimate for earnings is currently at 95 cents per share, with revenues expected to be $3.24 billion [1]. - The earnings surprise history shows that Alcoa has consistently outperformed estimates, with an average surprise of 39.3% over the last four quarters [2]. Earnings Prediction - Alcoa has an Earnings ESP of +0.53%, with the Most Accurate Estimate at 96 cents per share, indicating a favorable outlook for an earnings beat [4][3]. Segment Performance - The Aluminum segment is projected to see total sales of $2.45 billion, reflecting a 29% increase year-over-year, driven by demand in electrical and packaging markets [5]. - Conversely, the Alumina segment is expected to report total sales of $1.32 billion, indicating a 46% decline from the previous year due to lower shipments and trading activity [6]. Strategic Developments - Recent partnerships and acquisitions, including a joint venture for the San Ciprián site and the acquisition of Alumina Limited, are expected to enhance Alcoa's production capacity and market position [8][5]. Market Performance - Alcoa's shares have increased by 54.2% over the past three months, outperforming both the Zacks Metal Products - Distribution industry and the S&P 500 [10]. Valuation Metrics - The stock is currently trading at a forward P/E ratio of 12.50X, slightly below the industry average of 12.82X, suggesting potential upside [13]. Investment Thesis - Alcoa's diversified product portfolio and strategic collaborations position it well for growth, particularly in the context of increasing demand for energy-efficient products and the impact of higher tariffs on aluminum imports [15][16].

Core Insights - Johnson & Johnson (JNJ) is set to report its fourth-quarter and full-year 2025 results on January 21, with consensus estimates for sales at $24.14 billion and earnings at $2.50 per share [1] - The earnings estimates for 2025 have slightly decreased from $10.87 to $10.83 per share, and for 2026 from $11.48 to $11.46 per share over the past 60 days [1] Earnings Estimates - Current earnings estimates for Q1, Q2, FY 2025, and FY 2026 are $2.49, $2.77, $10.83, and $11.46 respectively, showing a downward trend in estimates over the past 60 days [2] - JNJ has a history of exceeding earnings expectations, with an average earnings surprise of 3.75% over the last four quarters [2] Business Segment Performance - The Innovative Medicine segment is expected to show growth driven by key products like Darzalex, Tremfya, and Erleada, with sales estimates of $3.74 billion, $1.36 billion, and $936 million respectively [5] - The MedTech business has improved due to acquisitions and is expected to continue strong performance in cardiovascular and surgical units, with a sales estimate of $8.71 billion [10][11] Challenges and Competition - The launch of several biosimilars for Stelara has negatively impacted its sales, with an estimated decline of 1070 basis points in the third quarter and expected further decline in the fourth quarter [7] - Sales of Imbruvica are anticipated to decline due to competitive pressures and the redesign of Medicare Part D, with an estimate of $670 million [8][9] Future Outlook - JNJ plans to provide an updated financial outlook for 2026, expecting over 5% revenue growth, which is higher than the previous consensus estimate of 4.6% [12] - The company has advanced its pipeline significantly, with 10 new products expected to potentially deliver peak sales of $5 billion [22] Stock Performance and Valuation - JNJ shares have outperformed the industry, rising 48.7% over the past year compared to the industry growth of 24.1% [15] - The stock is currently trading at a price/earnings ratio of 19.01, higher than the industry average of 17.73 and above its five-year mean of 15.65 [18] Investment Considerations - JNJ's diversified business model, strong cash flows, and consistent dividend increases over 63 years make it a compelling investment despite current challenges [20][24]